Clinical Trials

  • Principal Investigator:

    Marcus Rebello Pereira, MD
    The primary objective is to determine whether using hearts from HIV+ donors for HIV+ recipients is safe with regard to major transplant-related and HIV-related complications. The primary outcome is patient survival at one year. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
  • Principal Investigator:

    Marcus Rebello Pereira, MD
    The primary objective is to determine whether using hearts from HIV+ donors for HIV+ recipients is safe with regard to major transplant-related and HIV-related complications. The primary outcome is patient survival at one year. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
  • Principal Investigator:

    Marcus Rebello Pereira, MD
    In this research study, we want to find out how well patients that receive a kidney from an HIV-positive (HIV+) donor do over 10 years compared to patients who receive a kidney from an HIV-negative (HIV-) donor. This research study is for adults who are HIV+ and are being evaluated for or are waitlisted to receive a kidney transplant. It is also available for adults who are HIV+ and previously received a kidney-only transplant under a HOPE Act protocol. To take part in this study you must be willing to accept a kidney from an HIV+ or HIV- donor. If you decide not to join this study, you will...
  • Principal Investigator:

    Marcus Rebello Pereira, MD
    The primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
  • Principal Investigator:

    Marcus Rebello Pereira, MD
    The primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
  • Principal Investigator:

    Michael T Yin, MD
    We are doing a research study to find out if Long-Acting Injectable anti-HIV medications will be more successful than standard pills for people who have a hard time taking their HIV pills. If you are over the age of 18 years old, have been prescribed HIV medications but have had difficulty getting undetectable viral load (when the levels of virus in the bloodstream are so low that they can't be measured), you may be eligible. You may receive up to $1100 for the first 5 months of participation. Contact us to find out more about this study.
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD, MPH
    We are looking for individuals over 18 years old who are interested in learning more about COVID-19 prevention research studies. We will ask you to complete a brief questionnaire to find out if you may be eligible for one of our studies. We can then schedule a phone call, teleconference, or in-person education visit so you can learn about the research we do and decide if you want to participate in one of our studies. Your responses to this questionnaire will be kept strictly confidential.
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD, MPH
    Do you identify as a woman or transgender person, or do you have a non-binary gender identity? Has a medical provider ever diagnosed you with a sexually transmitted infection or recommended PrEP/another HIV prevention method? We are conducting a study to understand attitudes and preferences regarding HIV prevention methods among people who do not have HIV. The study involves taking online surveys. Some surveys are compensated. Please reach out if you are interested in hearing more about the study.
  • Principal Investigator:

    Deborah A Theodore, MD
    This is a study for people with symptoms of long COVID. We are looking for people over the age of 18 who are interested in participating in a study to understand whether a mindfulness meditation intervention can help improve symptoms of long COVID. Study participation lasts 6 months and is fully remote.
  • Principal Investigator:

    Anne-Catrin Uhlemann, MD,MPH
    We want to examine if wastewater-based surveillance of SARS-CoV-2 is a valuable tool to detect SARS-CoV-2-positive individuals on campus prior to being identified by routine individual testing. We aim to enroll CU employees and students for active surveillance of SARS-CoV-2 carriage to be able to validate waste water surveillance findings. If successful this approach might inform targeted testing and can improve safety on campus.

Pages